Table 2. Distribution of growth factors (VEGF) and its receptors among cases and controls.
| Study phenotype variables | Non diabetic control (n=22) | Diabetic Control (n=20) | Diabetic Retinopathy (n=81) | P value |
|---|---|---|---|---|
| VEGF165a (pg/ml) |
108.9±39.9 |
123.6±45.09 |
208.5±93.23 |
<0.0001* |
| VEGF165b
(pg/ml) |
26.75±14.35 |
45.94±22.86 |
56.27±33.08 |
0.0002* |
| VEGF165a-b
(pg/ml) |
52.16±40.06 |
61.38±42.54 |
157.70±101.2 |
<0.0001* |
| VEGFR1
(ng/ml) |
26.97±10.38 |
21.00±16.75 |
19.81±16.14 |
0.15 |
| VEGFR2
(pg/ml) |
26.75±14.35 |
49.94±22.86 |
56.27±33.08 |
0.002* |
| VEGFR3
(pg/ml) |
23.45±19.99 |
17.34±15.02 |
17.68±14.46 |
0.3 |
| CMT (um) | - | 213±102 | 319±181 | <0.0001* |
Data presented in Mean±SD among the study groups. *p value significant *after multiple testing correction (Bonferroni’s correction). Adjusted p value after correction was 0.007.